Perspective Therapeutics (CATX) Piper Sandler 36th Annual Healthcare Conference summary

Pipeline overview and innovation

• Focus on radioligand therapies with a deep, patent-protected pipeline extending into the late 2030s.

• Lead programs target neuroendocrine tumors, melanoma (MC1R), and FAP alpha, with additional peptide-targeting assets in development.

• Pioneering pretargeting approaches combining antibodies and peptides for enhanced tumor targeting.

• Emphasis on optimizing pharmacokinetics and biodistribution for improved efficacy and safety.

Lead program: VMT-α-NET for neuroendocrine tumors

• VMT-α-NET aims to improve on Lutathera by using an alpha-emitting isotope and proprietary chelator for better biodistribution.

• Phase 1/2 data showed disease control in 8 of 9 patients at initial dose levels, with a clean safety profile.

• FDA granted fast-track designation for first-line use, pending further data at higher doses.

• Enrollment ongoing in Cohort 2B (five millicuries); higher dose escalation awaits FDA agreement.

• Additional follow-up and fourth-cycle data expected as patients continue treatment.

Comparative and safety insights

• Compassionate use data from India at 67 microcuries/kg showed rapid, clean responses, supporting higher dosing.

• U.S. data suggest higher doses may be needed for optimal efficacy; safety profile remains favorable with minimal grade 3 events.

• Renal safety monitored closely; no significant acute kidney issues observed, with rapid clearance via the bladder.